FLT3 inhibitor gilteritinib, recommended by NICE in the UK for the treatment of acute myeloid leukemia.

!----NICE recommends the use of Astellas' Xospata (gilteritinib) for the treatment of adult patients with acute myeloid leukemia (AML) that is positive, recurrent, or incurableAML is a rare invasive form of blood and bone marrow cancer that can be fatal within months if left untreatedGilteritinib is a second-generation FLT3 inhibitor that inhibits FLT3 interstitated repetition (ITD) and FLT3 tyrosine kinase domain (TKD), two common types of FLT3 mutations, accounting for approximately one-third of all AML casesabout 3,100 people in the UK are diagnosed with AML each year, a third of them with the FLT3 gene mutationFLT3 mutation leads to higher recurrence rates and lower survival ratesDespite progress in chemotherapy, the prognosis of AML patients remains poor and little progress has been made in improving the long-term prognosis of patientsNICE recommendations are based on DATA from the ADMIRAL III trial, which showed that patients who received the treatment of gilteritinib had significantly longer total survival compared to patients receiving the treatment of gilteritinib, and who were positive for FLT3 mutation AMLpatients treated with gilteritinib had a median median survival of 9.3 months, compared with 5.6 months of chemotherapy, with a one-year survival rate of 37% and 17%, respectively.